SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats

Alcohol

Volumn 32, Issue 2, 2004, Pages 101-111

  Knapp, Darin J ^a   Overstreet, David H ^a   Moy, Sheryl S ^a   Breese, George R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2C; Anxiety like behavior; Benzodiazepine antagonist; Corticotropin releasing factor; Ethanol withdrawal syndrome; Social interaction test

Indexed keywords

4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALCOHOL; BEMESETRON; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; FLUMAZENIL; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; ZOLPIDEM;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; MALE; MAZE TEST; NONHUMAN; RAT; RELAPSE; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY;

ALCOHOL DRINKING; AMINOPYRIDINES; ANIMALS; ANXIETY; ETHANOL; FLUMAZENIL; INDOLES; MALE; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 1242313226     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.alcohol.2003.08.007     Document Type: Article

References (84)

1. Andrews N., File S.E., Fernandes C., Gonzalez L.E., Barnes N.M. Evidence that the median raphe nucleus-dorsal hippocampal pathway mediates diazepam withdrawal-induced anxiety. Psychopharmacology (Berl). 130:1997;228-234
2. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl). 103:1991;227-232
3. A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 50:1998;291-313
4. Bilkei-Gorzó A., Gyertyán I., Lévay G. mCPP-induced anxiety in the light-dark box in rats - a new method for screening anxiolytic activity. Psychopharmacology (Berl). 136:1998;291-298
5. 1A-receptor agonist. At http://www.acnp.org/citations/ Npp07100303159/default.pdf. (Source of work cited in this article is online publication of 10 July 2003, previously noted pdf file. For reader information: subsequent advance online publication, 03 September 2003, doi:10.1038/sj.npp. 1300282; print publication, Neuropsychopharmacology 29, 470-482.)
6. Buck K.J., Heim H., Harris R.A. Reversal of alcohol dependence and tolerance by a single administration of flumazenil. J Pharmacol Exp Ther. 257:1991;984-989
7. Cappell H., LeBlanc A.E. Tolerance and physical dependence: do they play a role in alcohol and drug self-administration? Israel Y., Glaser F.B., Kalant H., Popham R.E., Schmidt W., Smart R.G. Research Advances in Alcohol and Drug Problems. vol. 6:1981;159-196 Plenum Press, New York
8. 1 receptor antagonists, CRA1000 and CRA1001. Eur J Pharmacol. 371:1999;205-211
9. Costall B., Domeney A.M., Gerrard P.A., Kelly M.E., Naylor R.J. Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol. 40:1988;302-305
10. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., Tyers M.B. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav. 36:1990;339-344
11. Criswell H.E., Breese G.R. Similar effects of ethanol and flumazenil on acquisition of a shuttle-box avoidance response during withdrawal from chronic ethanol treatment. Br J Pharmacol. 110:1993;753-760
12. Criswell H.E., Knapp D.J., Overstreet D.H., Breese G.R. Effects of ethanol, chlordiazepoxide, and MK-801 on performance in the elevated-plus maze and on locomotor activity. Alcohol Clin Exp Res. 18:1994;596-601
13. Doble A. New insights into the mechanism of action of hypnotics. J Psychopharmacol. 13:1999;S11-S20
14. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol. 169:1989;1-10
15. 2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology. 36:1997;601-608
16. Ebert U., Wlaź P., Löscher W. Anticonvulsant effects by combined treatment with a glycineB receptor antagonist and a polyamine site antagonist in amygdala-kindled rats. Eur J Pharmacol. 322:1997;179-184
17. Eraković V., Župan G., Mršić J., Simonić A., Varljen J. The influence of nicardipine and ifenprodil on the brain free arachidonic acid level and behavior in hypoxia-exposed rats. Prog Neuropsychopharmacol Biol Psychiatry. 21:1997;633-647
18. 1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav. 58:1997;747-752
19. File S.E., Andrews N., al-Farhan M. Anxiogenic responses of rats on withdrawal from chronic ethanol treatment: effects of tianeptine. Alcohol Alcohol. 28:1993a;281-286
20. File S.E., Andrews N., al-Farhan M., Wu P.Y. The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits. Alcohol Alcohol Suppl. 2:1993b;495-499
21. File S.E., Baldwin H.A., Hitchcott P.K. Flumazenil but not nitrendipine reverses the increased anxiety during ethanol withdrawal in the rat. Psychopharmacology (Berl). 98:1989;262-264
22. 1A receptor modulation of anxiety in two ethological animal tests. J Neurosci. 16:1996;4810-4815
23. File S.E., Hyde J.R. The effects of p-chlorophenylalanine and ethanolamine-O-sulphate in an animal test of anxiety. J Pharm Pharmacol. 29:1977;735-738
24. 1A receptor function. Pharmacol Biochem Behav. 62:1999;695-701
25. File S.E., Zharkovsky A., Gulati K. Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacology. 30:1991;183-190
26. File S.E., Zharkovsky A., Hitchcott P.K. Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 16:1992;87-93
27. Frye G.D., Chapin R.E., Vogel R.A., Mailman R.B., Kilts C.D., Mueller R.A., Breese G.R. Effects of acute and chronic 1, 3-butanedione treatment on central nervous system function: a comparison with ethanol. J Pharmacol Exp Ther. 216:1981;306-314
28. Gatch M.B., Wallis C.J., Lal H. Effects of NMDA antagonists on ethanol-withdrawal induced "anxiety" in the elevated plus maze. Alcohol. 19:1999;207-211
29. Gatch M.B., Wallis C.J., Lal H. Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. Alcohol. 21:2000;11-17
30. 1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res. 732:1996;145-153
31. 1A receptor function: a link between anxiety and depression? Pharmacol Biochem Behav. 59:1998;787-792
32. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology. 36:1997;793-802
33. Griebel G., Sanger D.J., Perrault G. The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Psychopharmacology (Berl). 124:1996;245-254
34. A receptor subunits in rat cortex in a region-specific manner. Alcohol Clin Exp Res. 24:2000;1137-1144
35. Harro J., Tõnissaar M., Eller M. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat. Neuropeptides. 35:2001;100-109
36. Hershon H.I. Alcohol withdrawal symptoms and drinking behavior. J Stud Alcohol. 38:1977;953-971
37. 3 receptor antagonists. Psychopharmacology (Berl). 104:1991;545-551
38. Horváth Z.C., Czopf J., Buzsáki G. MK-801-induced neuronal damage in rats. Brain Res. 753:1997;181-195
39. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. 1996;National Academy Press, Washington, DC. URL: http://oacu.od.nih.gov/regs/ guide/guidex.htm.
40. June H.L., Eggers M.W., Warren-Reese C., DeLong J., Ricks-Cord A., Durr L.F., Cason C.R. The effects of the novel benzodiazepine receptor inverse agonist Ru 34000 on ethanol-maintained behaviors. Eur J Pharmacol. 350:1998a;151-158
41. June H.L., Torres L., Cason C.R., Hwang B.H., Braun M.R., Murphy J.M. The novel benzodiazepine inverse agonist RO19-4603 antagonizes ethanol motivated behaviors: neuropharmacological studies. Brain Res. 784:1998b;256-275
42. Jung M.E., Wallis C.J., Gatch M.B., Lal H. Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal. Alcohol. 21:2000;161-168
43. Kampov-Polevoy A.B., Matthews D.B., Gause L., Morrow A.L., Overstreet D.H. P rats develop physical dependence on alcohol via voluntary drinking: changes in seizure thresholds, anxiety, and patterns of alcohol drinking. Alcohol Clin Exp Res. 24:2000;278-284
44. 2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol. 117:1996;427-434
45. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620
46. Knapp D.J., Duncan G.E., Crews F.T., Breese G.R. Induction of Fos-like proteins and ultrasonic vocalizations during ethanol withdrawal: further evidence for withdrawal-induced anxiety. Alcohol Clin Exp Res. 22:1998;481-493
47. Knapp D.J., Overstreet D.H., Breese G.R. Persistent effects of repeated ethanol withdrawal are blunted by pharmacological treatments during early withdrawal episodes. Alcohol Clin Exp Res. 25:2001;23A. (Abstract)
48. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 278:1997;52-58
49. Kumari M., Ticku M.K. Regulation of NMDA receptors by ethanol. Prog Drug Res. 54:2000;152-189
50. Lal H., Prather P.L., Rezazadeh S.M. Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: reversal by buspirone. Alcohol. 8:1991;467-471
51. 2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res. 17:1993;411-417
52. Lister R.G., Greenblatt D.J., Abernethy D.R., File S.E. Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat. Brain Res. 290:1984;183-186
53. 3 receptor antagonists in rats. Psychopharmacology (Berl). 121:1995;488-493
54. 1 subtype. Nat Neurosci. 3:2000;587-592
55. Menzaghi F., Rassnick S., Heinrichs S., Baldwin H., Pich E.M., Weiss F., Koob G.F. The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann N Y Acad Sci. 739:1994;176-184
56. Mereu G., Carcangiu G., Concas A., Passino N., Biggio G. Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors. Eur J Pharmacol. 179:1990;339-345
57. Merlo Pich E., Lorang M., Yeganeh M., Rodriguez de Fonseca F., Raber J., Koob G.F., Weiss F. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci. 15:1995;5439-5447
58. Meyer R.E. Anxiolytics and the alcoholic patient. J Stud Alcohol. 47:1986;269-273
59. 1 antagonists, CP154, 526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology. 25:2001;585-600
60. 3H]zolpidem binding. Alcohol Clin Exp Res. 22:1998;1485-1492
61. Moy S.S., Knapp D.J., Criswell H.E., Breese G.R. Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology (Berl). 131:1997;354-360
62. Moy S.S., Knapp D.J., Duncan G.E., Breese G.R. Enhanced ultrasonic vocalization and Fos protein expression following ethanol withdrawal: effects of flumazenil. Psychopharmacology (Berl). 152:2000;208-215
63. Naranjo C.A., Sellers E.M. Research Advances in New Psychopharmacological Treatments for Alcoholism. 1985;Excerpta Medica, New York
64. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Nakazato A., Kumagai T., Okubo T., Tomisawa K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther. 289:1999;926-935
65. Overstreet, D. H., Knapp, D. J., & Breese, G. R. (2000). Mechanisms involved in the acute anxiogenic effects of fluoxetine. Serotonin Club/Brain Research Bulletin conference, Serotonin: from Molecule to the Clinic (satellite to the Society for Neuroscience Meeting, New Orleans, USA, November 2-3); 109 (Abstract).
66. Overstreet D.H., Knapp D.J., Breese G.R. Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol Clin Exp Res. 26:2002;1259-1268
67. 2C antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berl). 167:2003;344-352
68. Pandey S.C. Neuronal signaling systems and ethanol dependence. Mol Neurobiol. 17:1998;1-15
69. 2A/2C receptors and these receptor-linked phosphoinositide system by ethanol. Behav Brain Res. 73:1996;235-238
70. - uptake in mesocorticolimbic regions of rat brain. Alcohol Clin Exp Res. 25:2001;1270-1275
71. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 14:1985;149-167
72. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav. 24:1986;525-529
73. A receptor subunit and splice variant expression in rats treated with chronic intermittent ethanol. Alcohol Clin Exp Res. 25:2001;819-828
74. 2C receptors. Brain Res Mol Brain Res. 23:1994;163-178
75. Prather P.L., Rezazadeh S.M., Lal H. Mianserin in the treatment of ethanol withdrawal in the rat: prevention of behaviors indicative of anxiety. Psychopharmacol Bull. 27:1991;285-289
76. Rassnick S., Heinrichs S.C., Britton K.T., Koob G.F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605:1993;25-32
77. 1C receptor agonist in rats observed following withdrawal from chronic ethanol. Alcohol. 10:1993;281-283
78. Schaffer A., Naranjo C.A. Recommended drug treatment strategies for the alcoholic patient. Drugs. 56:1998;571-585
79. Snell L.D., Claffey D.J., Ruth J.A., Valenzuela C.F., Cardoso R., Wang Z., Levinson S.R., Sather W.A., Williamson A.V., Ingersoll N.C., Ovchinnikova L., Bhave S.V., Hoffman P.L., Tabakoff B. Novel structure having antagonist actions at both the glycine site of the N-methyl-D-aspartate receptor and neuronal voltage-sensitive sodium channels: biochemical, electrophysiological, and behavioral characterization. J Pharmacol Exp Ther. 292:2000;215-227
80. Thatcher-Britton K., Koob G.F. Alcohol reverses the proconflict effect of corticotropin-releasing factor. Regul Pept. 16:1986;315-320
81. To C.T., Anheuer Z.E., Bagdy G. Effects of acute and chronic fluoxetine treatment on CRH-induced anxiety. Neuroreport. 10:1999;553-555
82. Tsuda M., Suzuki T., Misawa M. NMDA receptor antagonists potently suppress the spontaneous withdrawal signs induced by discontinuation of long-term diazepam treatment in Fischer 344 rats. Brain Res. 790:1998;82-90
83. 2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology. 41:2001;186-199
84. Yang X., Criswell H.E., Simson P., Moy S., Breese G.R. Evidence for a selective effect of ethanol on N-methyl-D-aspartate responses: ethanol affects a subtype of the ifenprodil-sensitive N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 278:1996;114-124